论文部分内容阅读
目的:比较慢性肾功能衰竭(CRF)病人不同透析方法下促红细胞生成素(EPO)在体内消除状况.方法:根据病人透析方式不同,分为血透(HD)、腹透(CAPD)及非透析(non-D)3组.静脉推注EPO 300 u/kg.采用放射免疫法测定血药浓度,计算药物动力学参数.结果:3组均呈一室模型.HD组与其他两组的(T_(1/2))及c_(max)有显著差异(P<0.05),但Cls、C_(24h)、AUC在3组间并无显著性差异.CAPD组透析液中EPO浓度仅为同一时间血浓度的1%～1.5%,而HD组透析液中EPO浓度未能测及.结论:不同透析方式对rHu-EPO药物动力学无明显影响,临床不需依此调整rHu-EPO用药.
OBJECTIVE: To compare the elimination status of erythropoietin (EPO) in vivo in patients with chronic renal failure (CRF) under different dialysis methods.Methods: According to different dialysis patients, patients were divided into HD, CAPD, The rats were randomly divided into 3 groups: non-D, EPO 300 u / kg, radioimmunoassay and pharmacokinetic parameters.Results: (P <0.05), but Cls, C_ (24h), AUC had no significant difference among the three groups.The concentration of EPO in dialysis solution of CAPD group was only At the same time the blood concentration of 1% to 1.5%, while HD group dialysate EPO concentration failed to test.Conclusion: Different dialysis methods have no significant effect on rHu-EPO pharmacokinetics, clinical need not adjust rHu-EPO medication .